SCHEMBL1018675

SCHEMBL1018675

Cc1nc(N(C)C)ncc1C(=O)NC1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.55
LMNA P02545 2/20 0.51
ALDH1A1 P00352 4/20 0.49
NR3C1 P04150 3/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
GLA P06280 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
CNR1 P21554 1/20 0.44
FLT3 P36888 2/20 0.44
TYRO3 Q06418 2/20 0.44
MERTK Q12866 2/20 0.44
GAS6 Q14393 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017688 1.00 HPGD (0.55) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1014078 0.99 HPGD (0.56) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1016181 0.83 LMNA (0.56) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1014942 0.83 LMNA (0.56) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1017876 0.83 LMNA (0.56) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL541539 0.83 FLT3 (0.53) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1013682 0.82 LMNA (0.54) HPGDLMNAALDH1A1NR3C1KDM4E
SCHEMBL1014628 0.79 RAB9A (0.53) HPGDLMNANR3C1RAB9ANPC1
SCHEMBL1015585 0.79 RAB9A (0.53) HPGDLMNANR3C1RAB9ANPC1
SCHEMBL1017870 0.77 POLB (0.64) HPGDLMNAALDH1A1NR3C1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102066335-A Substituted pyrimidin-5-carboxamides 281 ASTRAZENECA AB 2011-05-18 CN disclosed
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 HPGD 54/4885LMNA 4185/4885ALDH1A1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.